Alanyl-glutamine in peritoneal dialysis fluids - a randomized controlled phase I/II trial
Ontology highlight
ABSTRACT: In this open-label randomized controlled phase I/II trial, 20 stable peritoneal dialysis patients underwent two 4 h dwells with acidic glucose-based PDF, with and without 8 mM alanyl-glutamine (AlaGln) in a cross-over design. Unsupervised hierarchical clustering of transcriptomics data suggested specific effects of AlaGln in patients who had previously suffered from peritonitis.
ORGANISM(S): Homo sapiens
PROVIDER: GSE57070 | GEO | 2020/01/24
REPOSITORIES: GEO
ACCESS DATA